# PMVP catalysts: PMV Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/pmvp/catalysts

> PMV Pharmaceuticals, Inc. (PMVP) has 1 upcoming catalyst. The next is the rezatapopt NDA/BLA submission, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for PMVP?

PMV Pharmaceuticals, Inc. (PMVP) has 1 upcoming catalyst. The next is the rezatapopt NDA/BLA submission, Q1 2027. Press release filed with the SEC (EX-99): "Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027" [Calendar and source filings](https://sec-api.dev/companies/pmvp/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-350445, https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/companies/pmvp/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | PMV Pharmaceuticals, Inc. |
| Ticker | PMVP (Nasdaq) |
| SEC CIK | 1699382 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/pmvp |

## Cash runway

Cash $108.5M as of 2026-09-30; quarterly burn $18.2M; about 17.9 months of runway at that rate (XBRL company facts, accession 0001193125-26-454471).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [Mirvetuximab FDA approval](https://sec-api.dev/pdufa/mirvetuximab) | PMVP |  | completed, approved | "MIRASOL Phase 3 (N=453)56 Mirvetuximab soravtansine vs chemotherapy FDA approved for FR⍺-positive PROC Nov 2022 ADC, antibody-drug conjugate; CI, confidence interval; CT, chemotherapy; FR⍺, folate receptor alpha; mDoR, duration of response; MIRV, mirvetuximab soravtansine; mo, months; mOS, median overall survival; mPFS, median progression-free survival; ORR, overall response rate; PROC, platinum-resistant ovarian cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/d90438dex991.htm)) |
| Oct 2024 | [ONUREG (azacitidine) trial start](https://sec-api.dev/pdufa/azacitidine) | PMVP |  | completed | "In October 2024, we announced that we are collaborating with the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center to support an investigator-initiated Phase 1b study, which is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of rezatapopt monotherapy in combination with azacitidine in R/R AML and MDS patients harboring a TP53 Y220C mutation." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095014/pmvp-20251231.htm)) |
| March 3, 2025 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/pmvp-ex99_1.htm)) |
| May 9, 2025 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025067511/pmvp-ex99_1.htm)) |
| August 7, 2025 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/pmvp-ex99_1.htm)) |
| Sep 2025 | [PMV Pharmaceuticals, Inc. interim data readout](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | scheduled | "PMV Pharma plans to provide data from the interim analysis of the Phase 2 monotherapy portion of PYNNACLE in the middle of 2025 and anticipates a New Drug Application submission by the end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/pmvp-ex99_1.htm)) |
| September 10, 2025 | [Rezatapopt interim data readout](https://sec-api.dev/pdufa/rezatapopt) | PMVP | TP53 Y220C and KRAS wild-type advanced solid tumors | scheduled | "PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis data" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/pmvp-ex99_1.htm)) |
| November 12, 2025 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312525276000/pmvp-ex99_1.htm)) |
| March 6, 2026 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/pmvp-ex99_1.htm)) |
| May 12, 2026 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/pmvp-ex99_1.htm)) |
| August 14, 2026 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-ex99_1.htm)) |
| November 10, 2026 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526454467/pmvp-ex99_1.htm)) |
| Q1 2027 | [Rezatapopt NDA/BLA submission](https://sec-api.dev/pdufa/rezatapopt) | PMVP |  | scheduled | "Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526350445/pmvp-ex99_1.htm)) |

## Drugs

- [Rezatapopt](https://sec-api.dev/pdufa/rezatapopt): tp53 y220c and kras wild-type advanced solid tumors

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/pmvp/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PMVP catalysts: PMV Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/pmvp/catalysts

```bibtex
@misc{secapidev_companies_pmvp_catalysts_20261116,
  title        = {PMVP catalysts: PMV Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/pmvp/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_pmvp_catalysts_20261116","title":"PMVP catalysts: PMV Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/pmvp/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
